반응식
[CH2:1]([O:8][C:9]([N:11]1[CH2:16][CH2:15][N:14]([CH2:17][C:18]([C:20]2[CH:21]=[C:22]3[C:26](=[CH:27][C:28]=2[O:29][CH2:30][C:31]2[CH:36]=[CH:35][CH:34]=[CH:33][CH:32]=2)[NH:25][CH:24]=[C:23]3[CH3:37])=[O:19])[CH2:13][CH2:12]1)=[O:10])[C:2]1[CH:7]=[CH:6][CH:5]=[CH:4][CH:3]=1>CN(C(OC)OC)C>[CH2:1]([O:8][C:9]([N:11]1[CH2:16][CH2:15][N:14]([C:17]([C:18]([C:20]2[CH:21]=[C:22]3[C:26](=[CH:27][C:28]=2[O:29][CH2:30][C:31]2[CH:36]=[CH:35][CH:34]=[CH:33][CH:32]=2)[NH:25][CH:24]=[C:23]3[CH3:37])=[O:19])=[CH:9][N:11]([CH3:16])[CH3:12])[CH2:13][CH2:12]1)=[O:10])[C:2]1[CH:7]=[CH:6][CH:5]=[CH:4][CH:3]=1참가 물질
3
반응물 1
생성물 1
시약·촉매·용매 1
실험 절차
A solution of 4-[2-(6-benzyloxy-3-methyl-1H-indol-5-yl)-2-oxo-ethyl]-piperazine-1-carboxylic acid benzyl ester (0.661 g, 1.33 mmol) in DMFDMA (5 ml) was heated at 100° C. overnight. The solvent was removed in vacuo and the crude product purified by column chromatography in hexane/EtOAc (1:1) to afford the product (0.158 g, 22%). LC/MS: RT=5.33 min. 553 (MH+).
후처리
- customThe solvent was removed in vacuo
- customthe crude product purified by column chromatography in hexane/EtOAc (1:1)
출처 및 근거
- ORD 기록
- ord-c1e19cc227ec484eaef68e791d199131
- 출처 데이터셋
- uspto-grants-2009_11
- 특허 번호
- US07612201B2
연결된 노트
불러오는 중…